Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 859 citations

Trough Concentrations, Inflammation, Anti-inflammatory +5

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 451 citations

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

Stéphane Paul, Émilie Del Tedesco, Hubert Marotte et al. · Inflammatory Bowel Diseases · 2013 · 219 citations · Full text

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Konstantinos Papamichael, Karen A. Chachu, Ravy K. Vajravelu et al. · Clinical Gastroenterology and Hepatology · 2017 · 218 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Niels Vande Casteele, D. J. Buurman, Marieke G. G. Sturkenboom et al. · Alimentary Pharmacology & Therapeutics · 2012 · 207 citations